From: Factors associated with disease evolution in Greek patients with inflammatory bowel disease
 | Disease behaviour at diagnosis | |||
---|---|---|---|---|
Variable | B1 (N = 80) | B2 (N = 15) | B3 (N = 21) | Overall (N = 116) |
Follow-up (yr) | 10.8 ± 6.5 | 9.9 ± 4 | 10.4 ± 6.9 | 10.5 ± 6.4 |
Males | 46 (57.5%) | 12 (80%) | 12 (57.1%) | 70 (60.3%) |
Months to diagnosis | 44.6 ± 42.4 | 38.8 ± 45.9 | 26.2 ± 36.1 | 40.6 ± 42.1 |
A1 | 60 (75%) | 9 (60%) | 14 (66.6%) | 83 (71.5%) |
Positive family history | 10 (12.5%) | 2 (13.3%) | 3 (14.2%) | 17 (14.6%) |
Location of disease | Â | Â | Â | Â |
   L1 | 12 (15%) | 7 (46.6%)* | 6 (28.5%) | 25 (21.5%) |
   L2 | 25 (31.2%) | 2 (13.3%) | 3 (14.2%) | 30 (25.8%) |
   L3 | 34 (42.5%) | 5 (33.3%) | 12 (57.1%) | 51 (43.9%) |
   L4 | 9 (11.2%) | 1 (6.6%) | 0 | 10 (8.6%) |
Current smoking | 41 (51.2%) | 6 (40%) | 12 (57.1%) | 59 (50.8%) |
Continuous course | 17 (21.2%) | 3 (20%) | 3 (14.2%) | 23 (19.8%) |
Extraintestinal disease‡ | 43 (53.7%) | 6 (40%) | 8 (38%) | 57 (49.1%) |
Immunosuppressives | 38 (47.5%) | 3 (20%)* | 9 (42.8%) | 50 (43.1%) |
Major operations†| 14 (17.5%) | 11 (73.3%)* | 10 (47.6%)* | 35 (30.1%) |
   At diagnosis | 2 (2.5%) | 9 (60%)* | 7 (33.3%)* | 18 (15.5%) |
   After diagnosis | 12 (15%) | 2 (13.3%) | 3 (14.2%) | 17 (14.6%) |